Research ArticleOpen AccessGoogle Scholar indexed
Improved All Cause and Cardiovascular Mortality and Morbidity by Empagliflozin: Too Good to Be True!
Broad Lawns Medical Center and Veterans Affairs Medical Center, Des Moines University, Des Moines, USA
University of Iowa, Iowa City, USA
- 1 Broad Lawns Medical Center and Veterans Affairs Medical Center, Des Moines University, Des Moines, USA
- 2 University of Iowa, Iowa City, USA
Journal of Diabetes Mellitus·Volume 06 (2016)·Pages 132–135·Published 31 March 2016·DOI10.4236/jdm.2016.62013
Copy link · social · email
Abstract
It was interesting to read the recent article regarding the efficacy of Empagliflozin in reducing all cause and cardiovascular mortality [1]. Superficially, the report appears to be very promising. However, the methodology, the results and the conclusions deserve and need further scrutiny and validation for several reasons.
KeywordsReview Paper
- Zinman, B., Wanner, C., Lachin, J.M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O.E., Woerle, H.J., Broedl, U.C. and Inzucchi, S.E., EMPA-REG Outcome Investigators (2015) Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. The New England Journal of Medicine, 373, 2117-2128.
- UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive Blood-Glucose Control with Sulphonylureas or Insulin Compared with Conventional Treatment and Risk of Complications in Patients with Type 2 Diabetes (UKPDS 33). The Lancet, 352, 837-853. http://dx.doi.org/10.1016/S0140-6736(98)07019-6
- UK Prospective Diabetes Study (UKPDS) Group (1998) Effect of Intensive Blood-Glucose Control with Metformin on Complications in Overweight Patients with Type 2 Diabetes (UKPDS 34). The Lancet, 352, 854-865. http://dx.doi.org/10.1016/S0140-6736(98)07037-8
- Kabadi, U.M. (2002) United Kingdom Prospective Diabetes Study: A Different Perspective. Endocrine Practice, 8, 61-64. http://dx.doi.org/10.4158/EP.8.1.61
- Holman, R.R., Paul, S.K., Bethel, M.A., Matthews, D.R. and Neil, H.A. (2008) 10-Year Follow-Up of Intensive Glucose Control in Type 2 Diabetes. The New England Journal of Medicine, 359, 1577-1589. http://dx.doi.org/10.1056/NEJMoa0806470
- Seaquist, E.R., Miller, M.E., Bonds, D.E., Feinglos, M., Goff Jr., D.C., Peterson, K. and Senior, P., ACCORD Investigators (2012) The Impact of Frequent and Unrecognized Hypoglycemia on Mortality in the ACCORD Study. Diabetes Care, 35, 409-414. http://dx.doi.org/10.2337/dc11-0996
- Hanefeld, M., Duetting, E. and Bramlage, P. (2013) Cardiac Implications of Hypoglycaemia in Patients with Diabetes: A Systematic Review. Cardiovascular Diabetology, 21, 135.
- Tsujimoto, T., Yamamoto-Honda, R., Kajio, H., Kishimoto, M., Noto, H., Hachiya, R., Kimura, A., Kakei, M. and Noda, M. (2014) Vital Signs, QT Prolongation, and Newly Diagnosed Cardiovascular Disease during Severe Hypoglycemia in Type 1 and Type 2 Diabetic Patients. Diabetes Care, 37, 217-221. http://dx.doi.org/10.2337/dc13-0701
- Chow, E., Bernjak, A., Williams, S., Fawdry, R.A., Hibbert, S., Freeman, J., Sheridan, P.J. and Heller, S.R. (2014) Risk of Cardiac Arrhythmias during Hypoglycemia in Patients with Type 2 Diabetes and Cardiovascular Risk. Diabetes, 63, 1738-1747. http://dx.doi.org/10.2337/db13-0468
- Khunti, K., Davies, M., Majeed, A., Thorsted, B.L., Wolden, M.L. and Paul, S.K. (2015) Hypoglycemia and Risk of Cardiovascular Disease and All-Cause Mortality in Insulin-Treated People with Type 1 and Type 2 Diabetes: A Cohort Study. Diabetes Care, 38, 316-322. http://dx.doi.org/10.2337/dc14-0920